Related references
Note: Only part of the references are listed.Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone et al.
NATURE MEDICINE (2021)
Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity
N. E. Donlon et al.
CANCER LETTERS (2021)
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Shugeng Gao et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A. Shu et al.
LANCET ONCOLOGY (2020)
Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
M. Wislez et al.
ANNALS OF ONCOLOGY (2020)
Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
B. Besse et al.
ANNALS OF ONCOLOGY (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio et al.
LANCET ONCOLOGY (2020)
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Joshua E. Reuss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer A Phase 2 Clinical Trial
David A. Palma et al.
JAMA ONCOLOGY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Immunotherapy in patients with early stage resectable nonsmall cell lung cancer
Katrien Ghysen et al.
CURRENT OPINION IN ONCOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti et al.
NATURE MEDICINE (2018)
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang et al.
CANCER RESEARCH (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Grit S. Herter-Sprie et al.
JCI INSIGHT (2016)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer
Enriqueta Felip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Stereotactic body radiation therapy: The report of AAPM Task Group 101
Stanley H. Benedict et al.
MEDICAL PHYSICS (2010)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Gary M. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas
Elizabeth W. Newcomb et al.
CLINICAL CANCER RESEARCH (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study
RC McGarry et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial
DC Betticher et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy
XL Liu-Jarin et al.
MODERN PATHOLOGY (2003)
Share Paper
